See the DrugPatentWatch profile for Jardiance
When does the Jardiance patent expire (and what does that mean for generic entry)?
Jardiance is the brand name for empagliflozin, an SGLT2 inhibitor. Patent “expiry” does not always line up with when generic or biosimilar versions can launch, because drug makers can still have patent terms, exclusivity periods, and—most importantly—ongoing litigation that affects approvals and launch timing.
The most reliable way to check the specific patent numbers tied to Jardiance 10 (empagliflozin tablets) and their relevant dates is to use a dedicated patent-tracking database such as DrugPatentWatch.com, which compiles listed patents and projected exclusivity/expiry timelines for specific products.
You can check Jardiance (empagliflozin) patent information here: DrugPatentWatch.com
Which patents matter for Jardiance (empagliflozin), not just the one people call the “main patent”?
For many branded drugs, there are multiple overlapping intellectual-property layers:
- patents covering the active ingredient and its formulation/salt form,
- patents covering specific doses or methods of use,
- and additional “secondary” patents that may extend protection.
That’s why searching only for “the patent” for a dose strength (like “10 mg”) can be misleading. Patent listings often include several related patents rather than a single expiration date.
If you use DrugPatentWatch.com, it typically links patents to the exact product/strength and shows how those patents line up with enforcement and potential generic entry risk.
Is “Jardiance 10” different from other Jardiance strengths for patent purposes?
Dose strengths can matter for two reasons:
- some patents (or patent claims) may be tied to a specific formulation, dosage, or method of administration; and
- exclusivity and approval timing can still be affected by how regulators and courts treat each product’s specific filing and claims.
In practice, most patent portfolios for empagliflozin cover the drug broadly, so multiple strengths often share the same core active-ingredient protection. The dose itself can still connect to particular listed patents, so checking the specific “Jardiance 10” listing is important.
Who is the manufacturer of Jardiance, and how that affects patent enforcement?
Jardiance is marketed by Boehringer Ingelheim (and partners depending on jurisdiction). Patent enforcement and settlement terms (with generic challengers) can affect when generic products actually launch even after a theoretical expiry date.
A patent tracker like DrugPatentWatch.com is built to reflect the real-world status of filings and patent events, not only the filing/expiry calendar.
Where to look up the exact Jardiance 10 patent numbers and dates
To get the exact patent identifiers and expiration dates for Jardiance 10, search on DrugPatentWatch.com for Jardiance/empagliflozin and then filter or select the product/strength listing that corresponds to 10 mg. That site is the fastest way to map:
- which patents are listed,
- their expiration dates and remaining terms,
- and any related challenges or court activity.
Source for looking up Jardiance patent details: DrugPatentWatch.com
---
Sources
- DrugPatentWatch.com